RESUMEN
Classical Hodgkin's lymphoma is one of the most treatable lymphoproliferative diseases with current chemotherapy regimens. The 5-year overall survival rate among patients after initial chemotherapy reaches 95 %, however, despite the significant success achieved, the problem of refractoriness/relapse remains very relevant. A standard approach to the treatment of refractory/recurrent Hodgkin's lymphoma among young patients with preserved general status and chemoresponsive to salvage therapy tumor is high-dose consolidation chemotherapy followed by transplantation of autologous hematopoietic stem cells. The intensification of chemotherapy regimens is highly difficult task for a doctor during the COVID-19 pandemic, which requires careful assessment of a risk-benefit ratio. In current conditions, new targeted and immune drugs are used to overcome resistance and reduce toxicity among pretreated patients, which allows not only to improve the results of a treatment, but also to preserve the high quality of life among patients with extremely unfavorable prognosis. we show our experience of using a checkpoint inhibitor in combination with a dose-intensive regimen of DHAp (dexamethasone, cytarabine, cisplatin) in the treatment of a refractory classical Hodgkin's lymphoma followed by high-dose consolidation chemotherapy and allogeneic hematopoietic stem cells transplantation, among patients complicated with a new coronavirus infection in the post-transplant period. Copyright © 2022 ABV-Press Publishing House. All rights reserved.
RESUMEN
Very few studies with objective information about the incidence, clinical characteristics, and consequences of a new COVID- 19 disease in children have been published so far. Early evidence suggests that coronavirus infection is less harmful to children than to adults. There are still many questions related to the effects of SARS-CoV-2 on children with coinfection (RSV, rhinovirus, bokavirus, and adenovirus) and comorbidities (bronchial asthma, congenital heart defects, and diabetes mellitus). Even several studies will help to identify the main effects of coronavirus on the child’s organism and consequences of the disease, as well as to predict possible disorders and develop a rehabilitation strategy for such patients. We suggest using novel methods of medical rehabilitation with proven effectiveness in children with bronchopulmonary disorders associated with coronavirus infection.
RESUMEN
The review presents current literature data on the medical rehabilitation of children undergoing COVID-19. The clinical features and leading syndromes of COVID-19 in children, as well as primary lesions of organs and systems requiring the use of medical rehabilitation methods, are considered. Rehabilitation technologies are proposed depending on the leading clinical syndrome. Information on the main rehabilitation technologies used in children with the consequences of COVID-19 is necessary for the implementation of comprehensive medical rehabilitation at all stages of treatment and recovery.